Advancing Human Health: Sustainability in Elaia's Portfolio
As part of the 2024 Elaia Sustainability Report, we’re featuring startups from the portfolio that stand out for their commitment to ESG. Next up, those driving a better understanding of human health.
Dive into the full 2024 Sustainability Report at elaia.com/esg.
The continuous development of science and technology continues to drive better understanding of the human body. We partner in the development of human health outcomes, from drug discovery, new treatment options, and technology to assist existing healthcare practices.
Portfolio Case Study: HEPHAISTOS-Pharma
HEPHAISTOS-Pharma is an immunotherapy startup that is designing and developing sole-in-class engineered immune sensor modulators to tackle the biggest challenge in oncology: Tumor resistance to immunotherapy.
ONCO-Boost is the first product from HEPHAISTOS-Pharma’s platform. It stimulates the patients’ own immune system, strengthening both innate and adaptive immune systems, to reshape tumor Micro-Environment. ONCO-Boost can work both as a single agent and in combination with established immunotherapies that do not work against cold tumours, boosting their efficacy to breakthrough levels. Thanks to its intravenous administration, ONCO-Boost is the first immunostimulant to demonstrate simultaneous efficacy against both primary tumours and metastases.
Portfolio Case Study: Hema.to
Hema.to is a deep tech AI company solving measurement of blood cell data and thereby make an outsised and lasting impact on immune medicine: they want to make sure every patient gets the right treatment at the right time for their unique immune systems.
Cytometry, the clinical analysis of blood data, is a time consuming exercise, coupled with shortages in laboratory staff there was much scope for the system to be improved upon. Hema.to wants to improve the system by using its cloud-based machine learning platform to personalise the analysis and bring ‘precision diagnostics to immune medicine’.